Clinical trials: Open Label
DIRA
Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
Background: Deficiency of the IL-1 receptor antagonist (DIRA) is a condition that causes repeated episodes of inflammation. People with DIRA can have rashes, fever, and joint pain.
- Trial name
- NCT01801449
- Testing
- Rilonacept
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Irritable Bowel Syndrome With Constipation, Functional Constipation
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation participants) of linaclotide exposure that will enroll pediatric participants…
- Trial name
- NCT04166058
- Testing
- Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 381 people
- Sponsor
- AbbVie
Ureter Injury
Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric Patients
This is an open-label, multicenter study to evaluate the safety, pharmacokinetics, and conspicuity of a weight-based Bludigo® dose (0.05 mL/kg rounded up (if necessary) to a minimum of 0.5 mL and not to exceed 2.5 mL) when used…
- Trial name
- NCT06448143
- Testing
- Indigotindisulfonate sodium 0.8% injection
- Volunteers
- 18 people
- Sponsor
- Prove pharm
HIV Infections
Growth Hormone Treatment of Children With HIV-Associated Growth Failure
The purpose of this study is to determine the effectiveness of recombinant human growth hormone (r-hGH) on growth in HIV-infected children.
- Trial name
- NCT00006143
- Testing
- Somatropin
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 102 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tourette's Syndrome, Tic Disorders
Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder
The purpose of this study is to determine if Abilify will reduce tics (repetitive, uncontrollable movements or vocalizations) in children and adolescents ages 7-18 with Tourette's Disorder (TD) or a chronic motor tic disorder…
- Trial name
- NCT00241176
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- NYU Langone Health
Functional Constipation (FC)
Efficacy of Notrande Shuhuajun Probiotic Supplement on Lmproving Constipation in Preschool Children
The goal of this interventional study is to evaluate the effectiveness of Notrande Shuhuajun Probiotic Supplement intake on the improvement of functional constipation in preschool children (3-6 years old).
- Trial name
- NCT07002489
- Testing
- Nuotelande Shuhuajun Study Product
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Shandong Sibote Biotechnology Co., Ltd.
Adenotonsillectomy, Postoperative Pain
Preoperative Celecoxib and Acetaminophen Versus Acetaminophen Alone for Pain Control After Pediatric Adenotonsillectomy
This is an open-label randomized study of approximately 500 pediatric patients (2-18 years of age, weighing more than 10 kg) undergoing adenotonsillectomy.
- Trial name
- NCT07870447
- Testing
- Celecoxib, Acetaminophen, Dexamethasone
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- NYU Langone Health
Acne
Combination Treatment for Moderate to Severe Acne
To determine if a combination of three currently approved acne products are safe and effective for the treatment of moderate to severe acne
- Trial name
- NCT01206348
- Testing
- Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide
- Where
- 10 sites in United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Medicis Global Service Corporation
TNF-receptor Associated Periodic Syndromes (TRAPS)
Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).
This trial will assess the safety and efficacy of ACZ885 in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS).
- Trial name
- NCT01242813
- Testing
- ACZ885
- Where
- 6 sites in Ireland, Italy and 1 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Melanoma
A Study of Vemurafenib in Participants With Metastatic Melanoma
This multi-center study evaluates the safety and efficacy of vemurafenib in participants with BRAF V600 mutation-positive, surgically incurable, and unresectable Stage IIIC or IV (American Joint Committee on Cancer [AJCC])…
- Trial name
- NCT01307397
- Testing
- Vemurafenib
- Where
- 280 sites in Albania, Argentina and 42 more
- Volunteers
- 3,219 people
- Sponsor
- Hoffmann-La Roche
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to evaluate the clinical efficacy and safety of Camidanlumab Tesirine (ADCT-301) in participants with relapsed or refractory Hodgkin Lymphoma (HL).
- Trial name
- NCT04052997
- Testing
- Camidanlumab Tesirine
- Where
- 73 sites in United States, Belgium and 9 more
- Volunteers
- 117 people
- Sponsor
- ADC Therapeutics S.A.
Asthma
Plasma Levels of MK0633 in Children Ages 6-12 (0633-023)
To evaluate the safety, tolerability and plasma levels of single oral doses of MK0633 in pediatric asthma patients ages 6 to less than 12 years.
- Trial name
- NCT00751413
- Testing
- Comparator: MK0633
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Candidates for Systemic Therapy for Psoriasis, Psoriasis
A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis
An open-label, multi-center study to establish psoriasis control of moderate to severe plaque psoriasis with Raptiva therapy administered subcutaneously for 24 weeks.
- Trial name
- NCT00287118
- Testing
- Efalizumab
- Where
- Switzerland
- Volunteers
- 189 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Prodromal Schizophrenia, Prodromal Psychosis
Aripiprazole Treatment of the Prodrome
The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole. This drug has been approved for treating symptoms associated with schizophrenia and is associated with fewer side effects.
- Trial name
- NCT00169949
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Gaucher Disease
Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase
This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.
- Trial name
- NCT00712348
- Testing
- Taliglucerase alfa
- Where
- 10 sites in United States, Australia and 4 more
- Volunteers
- 31 people
- Sponsor
- Pfizer
Pneumococcal Vaccines
Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®
The purposes of this study are assess the immunological response (measure the amount of antibodies, i.e. proteins that fight off germs) produced by children after they have been given the 13-valent pneumococcal vaccine (13vPnC)…
- Trial name
- NCT01392378
- Testing
- 13-valent pneumococcal conjugate vaccine, INFANRIX hexa, Paracetamol
- Where
- 14 sites in Poland
- Volunteers
- 908 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hemophilia B
An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B
The sample size of 12 male Chinese subjects are based on the CFDA requirement for a China PK study and to support the registration in China.
- Trial name
- NCT02213250
- Testing
- BENEFIX
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- Pfizer
Progression-free Survival, Overall Survival
Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade osteosarcoma is dismal and unchanged over the last decades.
- Conditions
- Progression-free Survival, Overall Survival, Clinical Benefit Rate, Toxicity
- Trial name
- APFAO (NCT03359018)
- Testing
- Apatinib, SHR-1210
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- Peking University People's Hospital
CTNNB1 Neurodevelopmental Syndrome
Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome
The goal of this first in human, phase I/II clinical trial is to evaulate the safety, tolerability, and preliminary efficacy of AAV9 mediated gene replacement therapy (Urbagen) in paediatric patients with CTNNB1…
- Trial name
- GAIN-CTNNB1 (NCT07270549)
- Testing
- Urbagen gene addition therapy, Sirolimus, Methylprednisolone (Corticosteroid)
- Where
- Slovenia
- Volunteers
- 12 people
- Sponsor
- CTNNB1 Foundation
Acne Vulgaris
Sarecycline Truncal Acne Safety and Efficacy Response
The purpose of this study is to determine the efficacy and safety of oral sarecycline 1.5 mg/kg/day in truncal acne. Patients with moderate to severe acne vulgaris will be observed over a period of 12 weeks.
- Trial name
- TASER (NCT05010538)
- Testing
- Sarecycline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Angela Moore
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.